View Financial HealthAscelia Pharma 配当と自社株買い配当金 基準チェック /06Ascelia Pharma配当金を支払った記録がありません。主要情報n/a配当利回り-108.2%バイバック利回り総株主利回り-108.2%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jul 13Ascelia Pharma Provides Update On Orviglance Following Complete Response Letter From FDAAscelia Pharma AB (publ) provides an update following the recent publication of the Complete Response Letter (CRL) by the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Orviglance. As previously communicated, Ascelia Pharma is preparing for a Type A meeting with the FDA to obtain a detailed understanding of the matters outlined in the CRL and to find an expedited path forward for Orviglance. Ascelia views the FDA concerns in the clinical section of the CRL as related to the image reading process and is providing additional factual context to clarify position. Ascelia considers the pivotal phase 3 study ASC-Man-P016 (“SPARKLE”) to be an adequate and well-controlled study, and the SPARKLE dataset provides a comprehensive and robust basis for evaluating the clinical performance of Orviglance. The SPARKLE study was conducted in accordance with the study protocol and generated a comprehensive imaging dataset. Image acquisition included all planned MRI sequences, including T1-weighted, T2-weighted and diffusion-weighted imaging (DWI) sequences. Manganese, the active substance in Orviglance, is a T1 enhancing compound. Issues in the initial image reading process meant that no conclusions on efficacy can be made based on the scoring by those image readers. Based on a thorough analysis, a new image reading process was subsequently implemented using new independent, blinded image readers with no prior knowledge of the SPARKLE images or prior reading results. The image re-read was conducted under predefined procedures to support a consistent and rigorous assessment of the imaging data. The initial image reading issues and the resulting approach for evaluation were discussed with the FDA and the agency’s feedback was incorporated into the NDA submission. The Company also notes that certain questions raised by the FDA relate to product documentation. Ascelia expects to address these matters in the near term. Ascelia intends to provide a further update following the planned meeting with the FDA and receipt of the official meeting minutes. Footnote: Pan D . Manganese-based MRI contrast agents: past, present and future. Tetrahedron. 1et al2011 Nov. 4;67(44):8431-8444. doi: 10.1016/j.tet.2011.07.076. PMID: 22043109; PMCID: PMC3203535.Buy Or Sell Opportunity • Jul 07Now 90% undervalued after recent price dropOver the last 90 days, the stock has fallen 100% to €0.0001. The fair value is estimated to be €0.001, however this is not to be taken as a buy recommendation but rather should be used as a guide only.Breakeven Date Change • Jul 06Forecast breakeven date pushed back to 2027The 3 analysts covering Ascelia Pharma previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 95% to 2026. The company is expected to make a profit of kr9.67m in 2027. Average annual earnings growth of 137% is required to achieve expected profit on schedule.お知らせ • Jan 23Ascelia Pharma AB (publ) Announces Departure of Julie Waras Brogren as Deputy CEOAscelia Pharma AB (publ) announced that Deputy CEO Julie Waras Brogren will leave the company to take up a CEO position in another company. Julie Waras Brogren joined Ascelia Pharma in January 2020 as Chief Commercial Officer and became Deputy CEO in October 2022. Since August 2023, she has also held the role of CFO. Julie will stay with Ascelia Pharma to ensure a successful transition of activities and to support the onboarding of the new incoming CFO, Anton Hansson.決済の安定と成長配当データの取得安定した配当: 7ZAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: 7ZAの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Ascelia Pharma 配当利回り対市場7ZA 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (7ZA)n/a市場下位25% (DE)1.6%市場トップ25% (DE)4.7%業界平均 (Biotechs)2.3%アナリスト予想 (7ZA) (最長3年)n/a注目すべき配当: 7ZAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: 7ZAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: 7ZAの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: 7ZAが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/24 22:37終値2026/07/24 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ascelia Pharma AB (publ) 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関null nullABG Sundal Collier SponsoredLars HevrengDanske BankMaria Karlsson OsipovaDNB Carnegie Commissioned Research3 その他のアナリストを表示
お知らせ • Jul 13Ascelia Pharma Provides Update On Orviglance Following Complete Response Letter From FDAAscelia Pharma AB (publ) provides an update following the recent publication of the Complete Response Letter (CRL) by the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Orviglance. As previously communicated, Ascelia Pharma is preparing for a Type A meeting with the FDA to obtain a detailed understanding of the matters outlined in the CRL and to find an expedited path forward for Orviglance. Ascelia views the FDA concerns in the clinical section of the CRL as related to the image reading process and is providing additional factual context to clarify position. Ascelia considers the pivotal phase 3 study ASC-Man-P016 (“SPARKLE”) to be an adequate and well-controlled study, and the SPARKLE dataset provides a comprehensive and robust basis for evaluating the clinical performance of Orviglance. The SPARKLE study was conducted in accordance with the study protocol and generated a comprehensive imaging dataset. Image acquisition included all planned MRI sequences, including T1-weighted, T2-weighted and diffusion-weighted imaging (DWI) sequences. Manganese, the active substance in Orviglance, is a T1 enhancing compound. Issues in the initial image reading process meant that no conclusions on efficacy can be made based on the scoring by those image readers. Based on a thorough analysis, a new image reading process was subsequently implemented using new independent, blinded image readers with no prior knowledge of the SPARKLE images or prior reading results. The image re-read was conducted under predefined procedures to support a consistent and rigorous assessment of the imaging data. The initial image reading issues and the resulting approach for evaluation were discussed with the FDA and the agency’s feedback was incorporated into the NDA submission. The Company also notes that certain questions raised by the FDA relate to product documentation. Ascelia expects to address these matters in the near term. Ascelia intends to provide a further update following the planned meeting with the FDA and receipt of the official meeting minutes. Footnote: Pan D . Manganese-based MRI contrast agents: past, present and future. Tetrahedron. 1et al2011 Nov. 4;67(44):8431-8444. doi: 10.1016/j.tet.2011.07.076. PMID: 22043109; PMCID: PMC3203535.
Buy Or Sell Opportunity • Jul 07Now 90% undervalued after recent price dropOver the last 90 days, the stock has fallen 100% to €0.0001. The fair value is estimated to be €0.001, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
Breakeven Date Change • Jul 06Forecast breakeven date pushed back to 2027The 3 analysts covering Ascelia Pharma previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 95% to 2026. The company is expected to make a profit of kr9.67m in 2027. Average annual earnings growth of 137% is required to achieve expected profit on schedule.
お知らせ • Jan 23Ascelia Pharma AB (publ) Announces Departure of Julie Waras Brogren as Deputy CEOAscelia Pharma AB (publ) announced that Deputy CEO Julie Waras Brogren will leave the company to take up a CEO position in another company. Julie Waras Brogren joined Ascelia Pharma in January 2020 as Chief Commercial Officer and became Deputy CEO in October 2022. Since August 2023, she has also held the role of CFO. Julie will stay with Ascelia Pharma to ensure a successful transition of activities and to support the onboarding of the new incoming CFO, Anton Hansson.